Two Sigma Investments, LP Enlivex Therapeutics Ltd. Transaction History
Two Sigma Investments, LP
- $59 Billion
- Q3 2025
A detailed history of Two Sigma Investments, LP transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Two Sigma Investments, LP holds 10,739 shares of ENLV stock, worth $10,524. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,739Holding current value
$10,524% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding ENLV
# of Institutions
30Shares Held
955KCall Options Held
0Put Options Held
0-
Citizens Financial Group Inc231KShares$226,7950.0% of portfolio
-
Morgan Stanley New York, NY174KShares$170,1520.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny157KShares$154,1460.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il68.9KShares$67,5570.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA54.9KShares$53,7530.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $18M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...